Frequency of complications after dermatological surgeries in the elderly

Dear Editor,

Population aging is a reality in Brazil. Both the incidence and prevalence of skin cancer are higher among the elderly. This explains the growing demand by the elderly for skin cancer treatments. Contrary to what many believe, dermatological surgeries (DS) in the elderly do not pose a higher risk of complications than in young individuals. Yet, there is some resistance by dermatologists to indicate surgery as the first-choice procedure for this population.

This study was developed to assess the risk of complications after DS was performed in the elderly population, aiming to evaluate and compare the postoperative complication rate (POCR) after DS in patients from three advanced age groups.

A retrospective, single-center study was carried out in a private service. A review of electronic medical records of patients over 65 years of age, operated on a day-hospital regimen, was performed between August 2012 and July 2018. The patients were divided into three groups, according to their age on the day of surgery. The elderly group (E) involved patients aged 65 to 74 years; patients aged 75 to 84 years were included in the very elderly (VE) group and patients aged 85 years and over were allocated to the extremely elderly (EE) group.

For patients submitted to more than one surgical procedure throughout the study, data from each intervention were computed separately. When multiple lesions were operated on during the same intervention, each one was computed separately aiming to calculate POCR (number of lesions that showed complications/number of lesions operated on). The postoperative complications (POCs) were classified into 4 types: dehiscence, hemorrhage, necrosis, and infection.

Almost all procedures were performed under local anesthesia or local anesthesia and sedation.

The data were analyzed using the BioEstat 5.3 program (Brazil), with a significance level of \( p \leq 0.05 \) for all tests. Pearson’s Chi-Square and Fisher’s Exact tests were used for comparison between the groups.

Detailed results are shown in Table 1. Regarding the POCR, there were no statistically significant differences between the groups (\( p > 0.05; \ E \times \text{VE} \ p = 0.308; \ VE \times \text{EE} \ p = 0.6832; \text{E} \times \text{EE} \ p = 0.1798 \)). The group with the lowest POCR was the EE (6.0%), albeit without statistical significance.

Comparing the POCR in relation to the surgical site, regardless of the age group, a higher percentage of complications was observed on the lower limbs (LL) surgeries (16.5%) and a lower percentage on the upper limbs (UL) surgeries (4.0%; \( p = 0.033 \)). LL surgeries also showed more complications than those on the trunk (\( p = 0.007237 \) and head and neck (HN; \( p = 0.000817 \)). There was no statistical difference between POCR involving UL, trunk, and HN when compared two by two (Fig. 1).

Among the patients in group I who had complications, the mean age was 70.1 years. The most common complication was surgical wound dehiscence, which occurred in 44.4% of the lesions that showed complications. Half of the lesions that progressed to POC were located on the trunk.

Of the 243 lesions excised on the LL of the patients, 17 (6.7%) developed some complications (Table 2). The mean age of the LL patients who showed complications was 79.4 years. Dehiscence was also the most common complication, observed in 36.8% of the lesions that had complications. The LL was the most affected site by POC (41.2%) in this group.

Of the 199 lesions excised on in EE patients, 12 (6.0%) showed complications (Table 2). The mean age of the EE group was 88.5 years. Infection was the most common POC (38.5%) and the LL was the most affected site by POC (50%).

There was no statistically significant difference between POCR in age groups from 65 years old onward. These data go against the simplistic view that elderly patients would...
have a higher risk of complications, leading dermatologists to give up the surgical option for these patients. Regarding the POCR by age group, the values found in the present investigation are similar to those observed in other studies involving elderly individuals, where these rates ranged from 5.7% to 10.6%.3,4

Changes resulting from aging and the presence of comorbidities in the elderly would place this group at a greater risk for POC. However, Imamura et al. demonstrated that in Japanese patients the POCR after DS was similar between the elderly aged between 75 and 80 years and those aged over 90 years.1 The finding that POCR did not increase with advancing age has been demonstrated in different studies, which showed that performing DS in the “extremely elderly” is as safe as in other elderly individuals.2,4

Regarding the risk of complications per operated body segment, it was observed that lesions on the lower limbs show more complications than those on the trunk or HN. The findings of the present study differ from those described by Paredela et al., who found no correlation between the excised site and complications.1 On the other hand, O’Neill et al. observed lower POCR in lesions located on the face.4 There is no consensual explanation about the reasons that lead to a higher risk of complications on the lower limbs. The authors suggest that the venous return impairment, which is frequently observed in the elderly population, combined with skin changes resulting from chronic venous stasis would contribute to higher POCR.

The lack of analysis of the surgical complexity, since more complex surgeries would have a greater chance of developing POC, is a possible study bias. The number of excised lesions in the same surgical procedure was not considered either, which also could interfere with the postoperative evolution. The use of certain medications, such as anticoagulants, antiplatelet agents, and the existence of comorbidities can interfere with the POCR. An additional study is being performed to assess the influence of these variables.

The POCR after DS did not vary significantly among three age groups of increasingly elderly individuals. Surgeries on the lower limbs showed higher POCR than those performed on other body segments, regardless of the assessed age group.

### Table 1
Epidemiological and clinical characteristics and post-surgical complications according to the age group.

|                      | Elderly (65–74 years) | Very elderly (75–84 years) | Extremely elderly (85 or + years) |
|----------------------|-----------------------|-----------------------------|-----------------------------------|
| Number of patients   | 74                    | 76                          | 55                                |
| Sex (F/M)            | 29/57                 | 24/84                       | 35/46                             |
| Mean age (years)     | 70,2                  | 76,8                        | 88,8                              |
| Median age (years)   | 70                    | 80                          | 88                                |
| Number of addressed lesions | 163                  | 243                         | 199                               |
| Number of surgical procedures | 86                  | 108                         | 81                                |
| Number of lesions with complications (%) | 16 (9,8%)  | 17 (7,0%)                  | 12 (6,0%)                         |

**Diagnosis:**
- **BCC (%)**
  - Elderly: 72 (44,2%)  
  - Very elderly: 107 (44%)  
  - Extremely elderly: 74 (37,2%)

- **SCC (%)**
  - Elderly: 23 (14,1%)  
  - Very elderly: 53 (21,8%)  
  - Extremely elderly: 56 (28,1%)

- **Melanoma (%)**
  - Elderly: 9 (5,5%)  
  - Very elderly: 7 (2,9%)  
  - Extremely elderly: 2 (1,0%)

- **Others**
  - Elderly: 59 (36,2%)  
  - Very elderly: 76 (31,3%)  
  - Extremely elderly: 67 (33,7%)

**Lesion location:**
- **Head and neck**
  - Elderly: 59 (36,2%)  
  - Very elderly: 115 (47,3%)  
  - Extremely elderly: 98 (49,2%)

- **Trunk**
  - Elderly: 62 (38,0%)  
  - Very elderly: 71 (29,2%)  
  - Extremely elderly: 53 (26,6%)

- **UL**
  - Elderly: 15 (9,2%)  
  - Very elderly: 21 (8,7%)  
  - Extremely elderly: 14 (7,1%)

- **LL**
  - Elderly: 27 (16,6%)  
  - Very elderly: 36 (14,8%)  
  - Extremely elderly: 34 (17,1%)

SAH, Systemic Arterial Hypertension; DM, Diabetes Mellitus; BCC, Basal Cell Carcinoma; SCC, Squamous Cell Carcinoma; UL, Upper Limbs; LL, Lower Limbs.

**Figure 1** Postoperative complication rates according to the operated body segment, regardless of the age group. UL, Upper Limbs; LL, Lower Limbs.
Table 2  Epidemiological, clinical and surgical characteristics of patients with postoperative complications, according to the age group.

| Sex:          | Elderly (65-74 years) | Very elderly (75-84 years) | Extremely elderly (85 or + years) | Total       |
|---------------|-----------------------|-----------------------------|-----------------------------------|-------------|
| Male          | 13 (81.3%)            | 14 (82.4%)                  | 7 (58.3%)                         | 34 (75.6%)  |
| Female        | 3 (19.7%)             | 3 (17.6%)                   | 5 (41.7%)                         | 11 (24.4%)  |
| Mean age:     | 70.1 years            | 79.4 years                  | 88.5 years                        |             |
| Median age:   | 70.0 years            | 79.0 years                  | 87.5 years                        |             |
| Comorbidities:|                       |                             |                                   |             |
| SAH           | 11 (68.8%)            | 14 (82.4%)                  | 11 (91.7%)                        | 36 (80.0%)  |
| DM            | 9 (56.3%)             | 7 (41.2%)                   | 3 (25.0%)                         | 19 (42.2%)  |
| Pacemaker     | 0                     | 1 (5.9%)                    | 3 (25.0%)                         | 4 (8.9%)    |
| Type of complication: |             |                             |                                   |             |
| Necrosis      | 3 (18.8%)             | 3 (17.6%)                   | 1 (8.3%)                          | 7 (15.6%)   |
| Dehiscence    | 8 (50.0%)             | 8 (47.1%)                   | 4 (33.3%)                         | 20 (44.4%)  |
| Hemorrhage    | 3 (18.8%)             | 1 (5.9%)                    | 1 (8.3%)                          | 5 (11.1%)   |
| Infection     | 3 (18.8%)             | 7 (41.2%)                   | 5 (41.7%)                         | 15 (33.3%)  |
| Other         | 1 (5.6%)              | 0                           | 2 (6.7%)                          | 3 (6.7%)    |
| Location of complication: |             |                             |                                   |             |
| Head and neck | 5 (31.3%)             | 6 (35.3%)                   | 4 (33.3%)                         | 15 (33.3%)  |
| Trunk         | 8 (50%)               | 3 (17.7%)                   | 1 (8.3%)                          | 12 (26.7%)  |
| UL            | 0                     | 1 (5.9%)                    | 1 (8.3%)                          | 2 (4.4%)    |
| LL            | 3 (18.7%)             | 7 (41.2%)                   | 6 (50%)                           | 16 (35.6%)  |

Financial support

None declared.

Authors’ contributions

Isabella Parente Almeida: Statistical analysis; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; critical review of the literature.

Maria Isabel Ramos Saraiva: Statistical analysis; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; critical review of the literature.

Maria Cristina de Lorenzo Messina: Approval of the final version of the manuscript; design and planning of the study; collection, analysis, and interpretation of data; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the manuscript.

Luiz Guilherme Martins Castro: Approval of the final version of the manuscript; design and planning of the study; collection, analysis, and interpretation of data; effective participation in research orientation; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the manuscript.

Conflicts of interest

None declared.
Melkerson-Rosenthal syndrome in children and adolescents: a series of seven cases

Dear editor,

Melkerson-Rosenthal syndrome (MRS)/orofacial granulomatosis is characterized by the triad of recurrent orofacial edema, recurrent peripheral facial palsy, and fissured tongue. The triad is found in 8% to 45% of cases; most patients present with the oligosymptomatic or monosymptomatic forms of the disease. The most common clinical manifestation is lip swelling (granulomatous cheilitis). The disease mainly affects young adults; pediatric cases are rarely described. A recent series described three cases and reviewed 116 previously published ones.

The cause of MRS is unknown. The authors of the present study demonstrated an increase in the expression of HLA A*02, HLA DRB1*11 to HLA DQB1*03 and a decrease in the levels of HLA A*01, HLA DRB1*04, HLA DRB1*07, and HLADQB1*02 in patients with MRS when compared to the control group, indicating genes that may predispose to or protect against the disease. An association between MRS and Crohn’s disease (CD) has been reported by some authors.

The histopathological findings of MRS include non-caseating granulomas similar to CD, which may suggest that MRS and CD might be part of the same clinicopathological spectrum.

The present report describes seven cases of MRS in children and adolescents, drawing attention to a possible association with CD.

The analyzed data from the cases diagnosed with granulomatous cheilitis/MRS/orofacial granulomatosis were: sex, age, lesion location, neurological impairment, and colonoscopy exams (Figs. 1–7 and Table 1). The diagnosis was confirmed by the histopathological analysis.

This sample represents the largest case series of children with MRS in Latin America. The authors’ oral mucosa diseases group conducts 900 medical consultations per year and, over a period of 20 years, only five pediatric MRS cases were seen (Cases 1 and 4 through 7); Cases 2 and 3 came from the private practice of one of the authors.

There was a predominance of male patients; the only female patient noticed symptoms at age 15. The cases reviewed by Savasta et al. showed a prevalence of female patients. Patient 1 is one of the youngest subjects ever reported (Fig. 1A).

Only patient 6 reported a previous bout of facial palsy, having also had an episode observed by the authors. Facial palsy affected 61/116 (52.6%) of the previously reported pediatric cases. Patient 5 had seizures of unknown cause; the neurology team associated them with MRS.

Cases 4, 5, 6 and 7 had fissured tongue; cases 4 and 6 had geographic tongue (Fig. 5A; Case 6 had concomitant fissured tongue). Geographic tongue is characterized by the presence of migrating areas of depapilation surrounded by a serpiginous edge. Histopathology is identical to that of psoriasis and is currently considered a mucosal manifestation of the latter. There is a significant association between psoriasis and Crohn’s disease. A fissured tongue usually occurs in cases of persistent geographic tongue; the two findings often coexist and represent the same process at different stages.

Cases 3 and 6 were diagnosed with CD, which was detected many years after the diagnosis of MRS, after controlling for orofacial symptoms. The routine investigation of MRS at the authors’ service currently includes periodic colonoscopy exams.

An association between MRS and CD has been reported. The authors’ group published the results of a study with HLA in 36 adult and pediatric cases and confirmed the association between MRS and CD in five cases (all had MRS HLA alleles and three had DC alleles). The genetic results obtained by the authors suggest that MRS and CD are distinct diseases, but they may be associated.

No treatment is effective for all cases of MRS; there are no controlled studies. There are no clinical elements that indicate the choice of a particular drug. It is believed that the selected drug should be used for at least three months before being considered a failure, as the response is slow. The authors’ preferred drug is thalidomide, based on their experience with adult patients. Five patients received thalidomide and two received dapson. Only one patient (Case 6) showed significant improvement with thalidomide. Patient 1 is slowly improving after one year of follow-up.